GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹5,046 Cr | ₹4,689 Cr | ₹4,201 Cr | ₹4,126 Cr | ₹4,021 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Current Liabilities |
---|---|
Mar2023 | ₹5,046 Cr |
Mar2022 | ₹4,689 Cr |
Mar2021 | ₹4,201 Cr |
Mar2020 | ₹4,126 Cr |
Mar2019 | ₹4,021 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹5,046 Cr | 7.59 | |
Mar2022 | ₹4,689 Cr | 11.63 | |
Mar2021 | ₹4,201 Cr | 1.82 | |
Mar2020 | ₹4,126 Cr | 2.61 | |
Mar2019 | ₹4,021 Cr | - |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹29,743.9 Cr | -2.4% | 7.4% | 88% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹361,916.0 Cr | 0.3% | -7.5% | 53.9% | Stock Analytics | |
CIPLA | ₹115,034.0 Cr | 1.1% | -4.8% | 56.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,929.0 Cr | 1.6% | 1.6% | 27.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,873.0 Cr | -1.9% | 10.7% | 21.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,322.0 Cr | 5.2% | -0.2% | 90.1% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | -2.4% |
7.4% |
88% |
SENSEX | -0.6% |
0.3% |
21.8% |
You may also like the below Video Courses